Floatz logo

tl-895

Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma

Telios Pharma, Inc.Phase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
MDM2 INHIBITOR AMG-232
Telios Pharma, Inc.
Phase 1/2CC

Same molecule, other indications

tl-895 is also rated in:

B-cell neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
48 / 100
View asset →
COVID-19Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →